Abstract：
Aim: Assess factors associated with first-line (1L) treatment for HR+/HER2- metastatic breast cancer. Materials & methods: A cross-sectional survey of 250 US oncologists was conducted. Correlations were calculated between treatment class and demographics, treatment perceptions and other clinical/nonclinical characteristics. Results: Efficacy and safety/tolerability were critical in oncologists\' 1L decision-making. CDK4/6i use positively correlated with proportion of Medicare and postmenopausal patients (r = 0.54-0.67). Chemotherapy use demonstrated positive correlations with perimenopausal and premenopausal patients and symptom burden (r = 0.31-0.42). Aromatase inhibitor (AI) monotherapy correlated positively with anticipated treatment compliance (r = 0.42). Conclusion: Efficacy and safety/tolerability were most important to 1L decision-making. Clinical characteristics corresponded with CDK4/6i and chemotherapy use. Anticipated compliance was associated with AI monotherapy use.
Patients in the USA with a certain type of metastatic breast cancer (mBC, i.e., HR+/HER2−) might get chemotherapy or hormone therapy alone instead of new and potentially better medicines called cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as their first treatment.Researchers wanted to understand how US cancer specialists decided the first treatment for this type of mBC. In a survey of 250 cancer specialists, researchers looked at different factors that might influence decision-making, including patient characteristics, doctors’ opinions about the treatments and other medical and non-medical features. This study also examined the connections between these factors and the cancer specialists’ choice of first treatment.Researchers found that cancer specialists care most about how well a treatment works and how safe it is when choosing the first treatment for HR+/HER2− mBC. They are more likely to use CDK4/6i if their patients have Medicare coverage or are older (i.e., women who have been through menopause). Chemotherapy is chosen if their patients are younger (i.e., women who are near and before menopause) or have more symptoms. Cancer specialists tend to choose first treatment with hormone therapy alone if they think their patients have a hard time following their treatment plan. The results showed that patient characteristics, doctors’ opinions of treatments and other medical and non-medical factors play a role in choosing treatment for HR+/HER2− mBC. By understanding these factors, researchers can work toward improving treatment choices for patients with this type of mBC.
Patients in the USA with a certain type of metastatic breast cancer (mBC, i.e., HR+/HER2−) might get chemotherapy or hormone therapy alone instead of new and potentially better medicines called cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as their first treatment.Researchers wanted to understand how US cancer specialists decided the first treatment for this type of mBC. In a survey of 250 cancer specialists, researchers looked at different factors that might influence decision-making, including patient characteristics, doctors’ opinions about the treatments and other medical and non-medical features. This study also examined the connections between these factors and the cancer specialists’ choice of first treatment.Researchers found that cancer specialists care most about how well a treatment works and how safe it is when choosing the first treatment for HR+/HER2− mBC. They are more likely to use CDK4/6i if their patients have Medicare coverage or are older (i.e., women who have been through menopause). Chemotherapy is chosen if their patients are younger (i.e., women who are near and before menopause) or have more symptoms. Cancer specialists tend to choose first treatment with hormone therapy alone if they think their patients have a hard time following their treatment plan. The results showed that patient characteristics, doctors’ opinions of treatments and other medical and non-medical factors play a role in choosing treatment for HR+/HER2− mBC. By understanding these factors, researchers can work toward improving treatment choices for patients with this type of mBC.
摘要：
目的：评估HR+/HER2-转移性乳腺癌一线（1L）治疗相关因素。材料与方法：对250名美国肿瘤学家进行了横断面调查。计算治疗类别和人口统计学之间的相关性，治疗观念和其他临床/非临床特征。结果：疗效和安全性/耐受性在肿瘤学家的1L决策中至关重要。CDK4/6i使用与医疗保险和绝经后患者比例呈正相关(r=0.54-0.67)。化疗使用与围绝经期和绝经前患者和症状负担呈正相关(r=0.31-0.42)。芳香化酶抑制剂(AI)单药治疗与预期治疗依从性呈正相关(r=0.42)。结论：疗效和安全性/耐受性对1L决策最重要。临床特征与CDK4/6i和化疗使用相对应。预期的依从性与AI单一疗法的使用有关。
美国患有某种类型转移性乳腺癌的患者(mBC，即，HR/HER2-）可能会单独接受化学疗法或激素疗法，而不是称为细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）的新的和潜在的更好的药物作为他们的第一治疗。研究人员想了解美国癌症专家如何决定这种类型的mBC的第一种治疗方法。在对250名癌症专家的调查中，研究人员研究了可能影响决策的不同因素，包括患者特征，医生对治疗以及其他医学和非医学特征的意见。这项研究还研究了这些因素与癌症专家选择首次治疗之间的联系。研究人员发现，癌症专家最关心的是治疗效果如何，以及在选择HR+/HER2-mBC的第一个治疗方法时的安全性。如果他们的患者有医疗保险保险或年龄较大，他们更有可能使用CDK4/6i(即，经历更年期的女性)。如果他们的患者更年轻，则选择化疗(即，接近更年期和更年期之前的女性）或有更多症状。如果癌症专家认为他们的患者很难遵循他们的治疗计划，他们倾向于选择单独使用激素治疗的第一治疗方法。结果显示，患者特征，医生的治疗意见和其他医学和非医学因素在选择HR+/HER2-mBC的治疗中起作用。通过了解这些因素，研究人员可以致力于改善这种类型的mBC患者的治疗选择。
美国患有某种类型转移性乳腺癌的患者(mBC，即，HR/HER2-）可能会单独接受化学疗法或激素疗法，而不是称为细胞周期蛋白依赖性激酶4/6抑制剂（CDK4/6i）的新的和潜在的更好的药物作为他们的第一治疗。研究人员想了解美国癌症专家如何决定这种类型的mBC的第一种治疗方法。在对250名癌症专家的调查中，研究人员研究了可能影响决策的不同因素，包括患者特征，医生对治疗以及其他医学和非医学特征的意见。这项研究还研究了这些因素与癌症专家选择首次治疗之间的联系。研究人员发现，癌症专家最关心的是治疗效果如何，以及在选择HR+/HER2-mBC的第一个治疗方法时的安全性。如果他们的患者有医疗保险保险或年龄较大，他们更有可能使用CDK4/6i(即，经历更年期的女性)。如果他们的患者更年轻，则选择化疗(即，接近更年期和更年期之前的女性）或有更多症状。如果癌症专家认为他们的患者很难遵循他们的治疗计划，他们倾向于选择单独使用激素治疗的第一治疗方法。结果显示，患者特征，医生的治疗意见和其他医学和非医学因素在选择HR+/HER2-mBC的治疗中起作用。通过了解这些因素，研究人员可以致力于改善这种类型的mBC患者的治疗选择。
